Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues

被引:31
|
作者
de Cerain, AL
Marín, A
Idoate, MA
Tuñón, MT
Bello, J
机构
[1] Univ Navarra, Dept Toxicol, E-31080 Pamplona, Spain
[2] Univ Navarra, Dept Pathol, E-31080 Pamplona, Spain
[3] Hosp de Navarra, Dept Pathol, Pamplona, Spain
关键词
carbonyl reductase; NAPDH P450 reductase; lung tumour; breast tumour; bioreductive agents;
D O I
10.1016/S0959-8049(98)00372-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of bioreductive agents in enzyme-directed bioreductive therapy has been proposed to take advantage not only of hypoxia in tumours, but also of the presence of reductases that metabolise such compounds. In this study, we studied the activities of NADPH cytochrome P450 reductase (P450R) and carbonyl reductase (CR) in 17 human lung tumours and 18 human breast tumours, together with the corresponding normal tissues. For lung cancer but not for breast cancer there was a significant difference in the CR activity between normal and tumour tissue. CR activity was increased with respect to the normal tissue between 2-fold and 40-fold indicating heterogeneity in tumour samples. No relationship was found between CR activity and the histological type, tumoral grade or TNM stage of the tumours. Although some variation in P450R activity in tumoral versus normal tissues was found in the majority of the samples studied, no significant differences could be demonstrated. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:320 / 324
页数:5
相关论文
共 50 条
  • [21] Flavodoxin as a model for the P450-interacting domain of NADPH cytochrome P450 reductase
    Jenkins, CM
    Waterman, MR
    DRUG METABOLISM REVIEWS, 1999, 31 (01) : 195 - 203
  • [22] Cytochrome P450 reductase maintains normal endothelial function
    Malacarne, P. F.
    Gajos-Draus, A.
    Siragusa, M.
    Mueller, N.
    Ratiu, C.
    Pflueger, B.
    Schroeder, K.
    Brandes, R.
    Rezende, F.
    ACTA PHYSIOLOGICA, 2019, 227
  • [23] CHRONIC ADMINISTRATION OF CHONDROITIN SULFATE DOES NOT AFFECT CYTOCHROME P450 AND NADPH P450 REDUCTASE
    Verges, J.
    Montell, E.
    Iovu, M. -O.
    Heroux, L.
    du Souich, P.
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2008, 30 : 138 - 138
  • [24] Allosteric modulation of cytochrome P450 enzymes by the NADPH cytochrome P450 reductase FMN-containing domain
    Burris-Hiday, Sarah D.
    Scott, Emily E.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2023, 299 (09)
  • [25] Cytochrome P450 reductase maintains normal endothelial function
    Malacarne, P. F.
    Gajos-Draus, A.
    Siragusa, M.
    Mueller, N.
    Ratiu, C.
    Pflueger-Mueller, B.
    Schroeder, K.
    Brandes, R. P.
    Rezende, F.
    ACTA PHYSIOLOGICA, 2019, 227
  • [26] Quantitative analyses of electrostatic interactions between NADPH-cytochrome P450 reductase and cytochrome P450 enzymes
    Voznesensky, Andrei I.
    Schenkman, John B.
    Journal of Biological Chemistry, 1994, 269 (22): : 15724 - 15731
  • [27] Cytochrome P450 / Cytochrome P450 Reductase Complex Formation Depends on NADPH: A Single Protein Tracking Study
    Brozik, James A.
    Barnaba, Carlo
    Taylor, Evan
    BIOPHYSICAL JOURNAL, 2018, 114 (03) : 198A - 198A
  • [28] Reduction of cytochrome b5 by NADPH-cytochrome P450 reductase
    Guengerich, FP
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2005, 440 (02) : 204 - 211
  • [29] High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli
    Iwata, H
    Fujita, K
    Kushida, H
    Suzuki, A
    Konno, Y
    Nakamura, K
    Fujino, A
    Kamataki, T
    BIOCHEMICAL PHARMACOLOGY, 1998, 55 (08) : 1315 - 1325
  • [30] Reconstitution premixes for assays using purified recombinant human cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5)
    Shaw, PM
    Hosea, NA
    Thompson, DV
    Lenius, JM
    Guengerich, FP
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 348 (01) : 107 - 115